血清AFP、CEA、CA125、CA199联合检测对消化系统恶性肿瘤的诊断价值分析

Analysis of the diagnostic value of serum AFP,CEA,CA125 and CA199 combined detection in malignant tumors of the digestive system

目的分析血清甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)联合检测对消化系统恶性肿瘤的诊断价值。方法选取50例消化系统恶性肿瘤患者作为观察A组、50例消化系统良性疾病患者作为观察B组,另选取50例健康体检人员作为对照组。三组均实施电化学发光法检测肿瘤标志物(血清AFP、CEA、CA125、CA199)水平。对比三组肿瘤标志物水平;对比不同类型消化系统恶性肿瘤患者肿瘤标志物水平。结果观察A组和观察B组AFP、CEA、CA125、CA199水平分别为(107.19±52.21)ng/ml、(42.14±1.39)ng/ml、(107.11±53.29)U/ml、(46.31±14.31)U/ml和(42.75±7.21)ng/ml、(2.59±1.24)ng/ml、(75.14±13.15)U/ml、(38.73±12.35)U/ml,均高于对照组的(2.39±1.14)ng/ml、(2.05±0.75)ng/ml、(17.68±3.15)U/ml、(15.39±3.12)U/ml(P<0.05);观察A组AFP、CEA、CA125、CA199水平均高于观察B组(P<0.05)。肝癌患者AFP(238.29±41.51)ng/ml高于大肠癌的(45.17±10.27)ng/ml、胃癌的(109.24±20.19)ng/ml、胰腺癌的(30.31±8.95)ng/ml(P<0.05);大肠癌患者CEA(94.04±26.51)ng/ml高于肝癌的(3.59±1.62)ng/ml、胃癌的(20.49±9.12)ng/ml、胰腺癌的(49.31±14.35)ng/ml(P<0.05);胃癌患者CA125(175.68±57.12)U/ml高于肝癌的(75.68±27.35)U/ml、大肠癌的(100.59±20.37)U/ml、胰腺癌的(79.65±29.65)U/ml(P<0.05);胰腺癌患者CA199(58.29±10.23)U/ml高于肝癌的(39.41±6.31)U/ml、大肠癌的(41.15±7.19)U/ml、胃癌的(47.41±8.01)U/ml(P<0.05)。结论将血清AFP、CEA、CA125、CA199联合检测用于消化系统恶性肿瘤临床诊断中具有较高的临床应用价值,同时各项指标在不同类型恶性肿瘤中表达均有不同,有利于鉴别诊断患者病症。

Objective To analyze the diagnostic value of serum alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)combined detection in malignant tumors of the digestive system.Methods 50 patients with malignant tumors of the digestive system were selected as observation group A,50 patients with benign diseases of the digestive system as observation group B,and another 50 healthy medical checkups were selected as control group.Tumor markers(serum AFP,CEA,CA125,CA199)were detected by electrochemiluminescence assay in all three groups.Comparison was made on levels of tumor markers in the three groups,as well as the levels of tumor markers in patients with different types of malignant tumors of the digestive system.Results The levels of AFP,CEA,CA125 and CA199 in observation group A and observation group B were(107.19±52.21)ng/ml,(42.14±1.39)ng/ml,(107.11±53.29)U/ml,(46.31±14.31)U/ml and(42.75±7.21)ng/ml,(2.59±1.24)ng/ml,(75.14±13.15)U/ml,(38.73±12.35)U/ml,which were higher than(2.39±1.14)ng/ml,(2.05±0.75)ng/ml,(17.68±3.15)U/ml,(15.39±3.12)U/ml in control group(P<0.05).The levels of AFP,CEA,CA125 and CA199 in observation group A were higher than those in observation group B(P<0.05).The AFP of(238.29±41.51)ng/ml in liver cancer patients was higher than that in colorectal cancer patients[(45.17±10.27)ng/ml],gastric cancer patients[(109.24±20.19)ng/ml]and pancreatic cancer patients[(30.31±8.95)ng/ml](P<0.05).The CEA of(94.04±26.51)ng/ml in colorectal cancer patients was higher than that in liver cancer patients[(3.59±1.62)ng/ml],gastric cancer patients[(20.49±9.12)ng/ml]and pancreatic cancer patients[(49.31±14.35)ng/ml](P<0.05).The CA125 of(175.68±57.12)U/ml in gastric cancer patients was higher than that in liver cancer patients[(75.68±27.35)U/ml],colorectal cancer patients[(100.59±20.37)U/ml]and pancreatic cancer patients[(79.65±29.65)U/ml](P<0.05).The CA199 of(58.29±10.23)U/ml in pancreatic cancer patients was higher than that in liver cancer patients[(39.41±6.31)U/ml],colorectal cancer patients[(41.15±7.19)U/ml],and gastric cancer patients[(47.41±8.01)U/ml](P<0.05).Conclusion The combined detection of serum AFP,CEA,CA125 and CA199 has high clinical application value in the clinical diagnosis of malignant tumors of the digestive system,and the expression of each index is different in different types of malignant tumors,which is conducive to the differential diagnosis of patients.